OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

Novo Nordisk A/S/  DK0062498333  /

Cboe Europe CXE
2024-05-13  3:35:03 PM Chg. - Volume Bid9:00:03 AM Ask9:00:03 AM Market Capitalization Dividend Y. P/E Ratio
907.00DKK - 790
Turnover: 715,012.40		 -Bid Size: - -Ask Size: - 3170.85 bill.DKK 1.02% 49.44
GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 05-07 Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
TeleTrader 04-25 Europe opens mostly down after corporate earnings
GlobeNewswire 04-22 Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire 04-22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 04-22 SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire 04-11 Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire 04-02 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 04-02 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
GlobeNewswire 03-28 Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire 03-27 Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire 03-25 Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire 03-18 Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire 03-15 University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...
GlobeNewswire 03-12 Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...
GlobeNewswire 03-12 ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOA...
GlobeNewswire 03-11 FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer
GlobeNewswire 03-07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire 03-07 Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Car...
GlobeNewswire 03-01 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire 02-28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire 02-28 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Cla...
TeleTrader 02-26 Zealand Pharma soars 30% on positive weight-loss drug results
GlobeNewswire 02-24 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Sec...